Title : CCNU + TMZ (CeTeG / NOA-09, phase 3 trial), full article
link : CCNU + TMZ (CeTeG / NOA-09, phase 3 trial), full article
CCNU + TMZ (CeTeG / NOA-09, phase 3 trial), full article
Finally, the full article is published (not only abstract):
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
"Between June 17, 2011, and April 8, 2014, 141 patients were randomly assigned to the treatment groups; 129 patients (63 in the temozolomide and 66 in the lomustine-temozolomide group) constituted the modified intention-to-treat population. Median overall survival was improved from 31·4 months (95% CI 27·7-47·1) with temozolomide to 48·1 months (32·6 months-not assessable) with lomustine-temozolomide (hazard ratio [HR] 0·60, 95% CI 0·35-1·03; p=0·0492 for log-rank analysis). A significant overall survival difference between groups was also found in a secondary analysis of the intention-to-treat population (n=141, HR 0·60, 95% CI 0·35-1·03; p=0·0432 for log-rank analysis). Adverse events of grade 3 or higher were observed in 32 (51%) of 63 patients in the temozolomide group and 39 (59%) of 66 patients in the lomustine-temozolomide group. There were no treatment-related deaths."
Thus Article CCNU + TMZ (CeTeG / NOA-09, phase 3 trial), full article
That's an article CCNU + TMZ (CeTeG / NOA-09, phase 3 trial), full article This time, hopefully can give benefits to all of you. well, see you in posting other articles.
You are now reading the article CCNU + TMZ (CeTeG / NOA-09, phase 3 trial), full article with the link address https://polennews.blogspot.com/2019/02/ccnu-tmz-ceteg-noa-09-phase-3-trial.html
0 Response to "CCNU + TMZ (CeTeG / NOA-09, phase 3 trial), full article"
Post a Comment